BBLG News and Press, Bone Biologics Corp From 11/02/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re getting right into the thick of it today with a look at the biggest pre-market stock movers for Tuesday. Source: f11photo/Shutterstock.com We’ve got earnings reports, analys...

Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that it closed a public offering of 1,510,455 units of securities at an offering price of $5.25 pe...

WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering PR Newswire JERSEY CITY, N.J. , Oct. 15, 2021 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execut...

WallachBeth Capital announces pricing of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering and Uplisting to the NASDAQ Capital Market PR Newswire JERSEY CITY, N.J. , Oct. 13, 2021 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of ...

Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its underwritten public offering of 1,510,455 units of securities at an offering price ...

Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model...

Bone Biologics ( OTCQB:BBLG ) has received  Human Research Ethics Committee (HREC) approval, for the first center of a pilot clinical trial to evaluate NB1 (NELL-1/DBX) in 30 patients in Australia. More news on: Bone Biologics Corporation, Healthcare stocks news, Read more ....

Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it received Human Research Ethics Committee (HREC) approval on March 20, 2019, for the first center of a multicenter pilot clinical...